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Summary: The serum concentrations of soluble interleukin-2 receptors and urine neopterin were studied in
82 patients with malignant lymphomas (25 patients with Hodgkin's disease and 57 patients with non-Hodgkin's
lymphoma.
Increases in soluble interleukin-2 receptors and in urinary neopterin were significantly correlated with the
clinical phase of the disease. The average values in both Hodgkirfs disease and non-Hodgkin's lymphoma
patients suffering from the disease in its active phase were significantly higher than those of patients in
complete remission. Neopterin concentrations (but not soluble interleukin-2 receptor concentrations) were
also elevated in clinical stages III —IV of each disease. Urinary neopterin correlated directly and significantly
with the erythrocyte sedimentation rate and inversely with haemoglobin. Finally, a longitudinal analysis
showed a general tendency for the markers to return to normal values, in accordance with the favourable
outcome of therapy; this was more evident for urinary neopterin than for soluble interleukin-2 receptors.
These findings seem to confirm that soluble interleukin-2 receptors and especially urinary neopterin can be
useful markers for monitoring and prognosis of malignant lymphomas.
Introduction __ t , , , · ,receptor. Both normal activated and neoplastic lym-
Interleukin-2 is a soluble lymphokine released by ac- phocytes release a soluble receptor for interleukin-2
tivated T helper lymphocytes, which promotes (soluble interleukin-2 receptors). These soluble recep-
^ ^ rr r^ * t^ ι ι. tors bind interleukin-2, and by competing with thea) the proliferation of T and B lymphocytes. , „ , ^ · ,_·,_· t• / receptors on the cell membrane, they may inhibit the
b) the cytotoxic activity of T lymphocytes and of interleukin-2-dependent immune responses (4 —6).
natural killer cells and lymphokine activated killer _ - , . . . , . r.„ , j - - r . . Recently, abnormally increased concentrations of m-cells, and , , · ~ ,terleukm-2 receptors have been reported in various
c) the secretion of immunoglobulin in B normal and diseases, both tumoral (lymphomatosis (7, 8) and
neoplastic lymphocytes (1—3). solid tumours (9, 10) and non-tumoral (autoimmune
T , t , . 0 . , . . ., . , . , . .. .~ and viral conditions, collagenosis (11 — 13)), whichInterleukin-2 is a glycoprotem that binds to specific r JW /. j-^- - j /* ' ' / · * ι * ι · ο " * \ Λ Λ feature different types of modification and/or acti-receptors (interleukin-2 receptors) expressed on the f t .
Λ n u r ^u *- * Λ -r Λ r» i u * vation of the immune system,cell membrane of the activated T and B lymphocytes J
and monocytes. An interleukin-2 receptor consists of Neopterin, which was isolated from human urine
two polypeptide chains (a and β) which, when in close more than a decade ago, is a pteridine compound
proximity to each other, constitute a high-affinity deriving from guanosine triphosphate. Pteridines are
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molecules that are active in various biological events
such as cell growth, regulation of immune responses
and amine synthesis, and modulation of the endocrine
system. Pteridine concentrations in cells and blood
rise during periods of intense cell proliferation, as in
the lymphocyte immune reaction and the replication
of certain types of tumour cells. Pteridines play a
specific role in the qualitative and quantitative mech-
anisms of interleukin-2-dependent lymphocyte re-
sponses in immune functions (14, 15). In tumours,
particularly in cases of haematological malignancies,
pteridines are metabolized to produce high concen-
trations of tetrahydrobiopterin in the blood, and of
biopterin and neopterin in the urine (16—18). An-
other point of major interest is that γ-interferon (pro-
duced by T-lymphocytes following stimulation by
tumour antigens and natural killer cells acitvated with
interleukin-2) induces the secretion, by macrophages,
of neopterin, which is then excreted in the urine.
Preliminary studies report increased urinary neopterin
in patients with lymphomas and carcinomas of the
genital-urinary tract and the lungs (19—21). Recently
it was reported that soluble interleukin-2 receptors
(22, 23) and urinary neopterin (24—30) concentra-
tions may be important markers not only in the mon-
itoring but also in the prognosis of neoplastic diseases.
In the light of the foregoing, we studied serum soluble
interleukin-2 receptor concentrations and urinary
neopterin concentrations in patients with Hodgkin's
disease and non-Hodgkin's lymphomas, which were
unaffected by other pathologies (autoimmune dis-
eases, collagenosis or viral infections) that might dis-
tort the findings.
Materials and Methods
Patients of both sexes between 20 and 80 years, 25 with Hodg-
kin's disease and 57 with non-Hodgkin's lymphomas were in-
vestigated. Soluble interleukin-2 receptors were determined in
the blood and neopterin in the urine (tab. 1).
Correlations were also sought between the concentrations of
soluble interleukin-2 receptors and urinary neopterin and the
clinical phase of the disease (activity versus remission). Prelim-
inary screening had shown that patients with complete or in-
complete remission (8 and 12 cases, respectively) could be
pooled, since their data overlapped; this also correlated with
extremely low numbers of residual tumour cells and a resulting
low immune response. Blood interleukin-2 receptors and urine
neopterin were measured in patients during the active phase of
the disease before treatment and in those during the remissive
phase 3 weeks after the end of induction therapy, when remis-
sion had been confirmed. The concentrations of the two mark-
ers in patients with active Hodgkirfs disease and non-Hodgkin's
lymphoma were also correlated with the clinical stage (Stages
I and II versus Stages III and IV of the Ann Arbor classifica-
tion), with the general symptoms (presence B, absence A) and
with the histological type (Rye Conference classification for
Hodgkin's disease and the Working Formulation of non-Hodg-
kin's lymphoma (31, 32)). In 8 cases, the 2 quantities were

































Legend: LP, Lymphocyte predominance; NS, Nodular sclero-
sis; MC, Mixed cellularity; DL, Lymphocyte deple-
tion.
assayed before and after the planned induction therapy with
confirmed remission in a longitudinal study. Other quantities
currently used in clinical monitoring (erythrocyte sedimentation
rate, haemoglobin, white blood corpuscles, lymphocytes and
monocytes, lactate dehydrogenase, a2-globulins, albumin) were
also taken into account.
Statistical analysis
Data were stored in a computerized data base (db4, Ashton
T te) and processed using the SPSS statistical package (SPSS
Inc.). Differences between the means of groups were tested for
significance with the non-parametric Mann-Whitney (Wilcoxon)
test. Relationships between soluble interleukin-2 receptors, uri-
nary neopterin and other quantities were investigated by cal-




Serum was frozen at — 20 °C, stored in small aliquots, then
assayed by an enzyme-linked immunosorbent assay (ELISA),
recently marketed for research purposes (Interleukin-2 Receptor
Test Kit from T-Cell Sciences Inc., Cambridge (MA), distrib-
uted by Medical Systems S. P. A.). It uses a inurine monoclonal
antibody for interleukin-2 receptors adsorbed in polystyrene
micro-traps to which the patient's serum is added; non-reactive
elements are washed away. A second murine monoclonal an-
tibody, specific for interleukin-2 receptors, and conjugated with
horseradish peroxidase, is then added to bind a second epitope
to the molecule captured by the first antibody. The interleukin-
2 receptor antibody conjugated with the free enzyme is removed
by further washing and the substrate is added. The reaction is
stopped and read at 490 nanometres. The mean absorption
value of paired samples is calculated from a standard curve
based on 4 points at different concentrations. Blood soluble
interleukin-2 receptor values are expressed in units (U) per litre.
Samples requiring dilution are diluted in their own buffer.
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Reference standards were first obtained from 150 subjects with
normal anamnesis and normal main metabolic functions, who
were free from acute or chronic illness. The readings ranged
from 116 to 402 χ ΙΟ3 U/l, in exact agreement with the data
reported in the literature.
Urinary neopterin (24, 28)
Morning urine samples were collected and frozen at — 20 °C
until analysis. Since urinary neopterin concentrations are re-
lated to urinary creatinine, both were measured to account for
physiological variations in urinary concentrations.
A Varian 5500 liquid Chromatograph equipped with a Varian
8085 autosampler was used, with a reversed-phase C18 analyt-
ical column run at 0.8 ml/min flow rate under isocratic condi-
tions. Separation was performed with Soerensen phosphate
buffer (pH 6.4, 15 mmol/1, flow 1 ml/min).
Creatinine was monitored at 235 nm with a Varian UV 200
detector. A Varian 2070 spectrophotometer was set at 360 nm
excitation wavelength and 420 nm emission wavelength, and
neopterin was quantified from the peak area using a Vista 402
System and the external standard method. Results were ex-
pressed as the neopterin to creatinine ratio.
Results
Serum interleukin-2 receptors and urinary neopterin
correlated closely with the active phase of the disease
(fig. la —d). The 8 patients with Hodgkin's disease in
remission and the 12 with non-Hodgkin's lymphoma
in remission exhibited highly-significant decreases in
the quantities in question, interleukin-2 receptors
tending to approach the upper normal threshold limit
(771 ± 450 χ 103 U/l and 610 ± 586 χ ΙΟ3 U/l,
respectively), while neopterin was practically normal
(173 ± 78 μιηοΐ/mol arid 198 ± 95 μιηοΐ/mol, re-
spectively). In the 17 patients with active Hodgkin's
disease and the 45 patients with active non-Hodgkirfs
lymphoma, there were highly-significant increases in
both interleukin-2 receptors (2363 ± 2876 χ 103U/1:
ρ = 0.003; 3634 ± 5667 χ ΙΟ3 U/l: p = 0.0003) and
neopterin (394 ± 295 μιηοΐ/mol: ρ = 0.002; 610
± 586 μιηοΐ/ιηοΐ: ρ < 0.0001); furthermore, in these
cases, the interleukin-2 receptor values did not vary
significantly with the clinical stage, whereas the neop-
terin values were significantly higher in stage III —IV
than in stage I—II patients in both Hodgkin's disease
and non-Hodgkin's lymphoma groups (525 ±317
μιηοΐ/mol versus 227 ± 97 μτιχοΐ/ηιοί, ρ = 0.018; 790
± 61 μιηοΐ/mol versus 422 ±194 μιηοΐ/mol,
p = 0.0003) (fig. Je—h). In relation to the presence
of B symptoms in no^Uodgkin's lymphoma patients,
but not in Hodgkin's disease patients, significantly
higher values were recorded only for urinary neopterin
(B: 974 ± 752 μιηοΐ/mol versus A: 555 ± 360 μπιοί/
mol, ρ = 0.023); also, only urinary neopterin corre-
lated directly and significantly with the erythrocyte
sedimentation rate (p = 0.003 R = 0.31) and in-
versely with haemoglobin (p = 0.000 R = —0.40).
There was a direct, though not statistically significant
correlation between soluble interleukin-2 receptors
and urinary neopterin.
In the Hodgkin's disease and non-Hodgkin's lym-
phoma groups, the histological subtype showed no
significant correlation with the grades of malignancy.
In the eight patients in the longitudinal study, there
was a general tendency for the markers to approxi-
mate to normal values when the outcome of therapy
was favourable; this was more evident for urinary
neopterin than for interleukin-2 receptors (fig. 2).
Discussion
Our findings, and those reported in the available
literature contain elements of considerable clinical and
biological interest.
Increases in blood soluble interleukin-2 receptors have
been observed both in patients with leukaemia (par-
ticularly T-cell lymphocytic leukaemia, hairy cell leu-
kaemia and chronic B-cell lymphocytic leukaemia)
and in those with lymphomas (non-Hodgkin's lym-
phoma, Hodgkin's disease), to the extent that blood
soluble interleukin-2 receptors might well be thought
to be of particular importance in the monitoring of
these diseases (23, 33 — 36). Similar increases have
been recorded in 70% of non-Hodgkin's lymphoma
patients; they are generally reported as being linked
to the extent of the disease and, as such, to serve as
an indicator of tumour bulk (23), but this is appar-
ently at variance with our findings. Our data indeed
show an increase in soluble interleukin-2 receptor
serum concentrations with advanced disease, but this
is not statistically significant, probably due to the
small number of patients and a wide dispersion of
individual values. The values tend to normalize fol-
lowing complete clinical remission after therapy. In
many cases, particularly in infancy, the increase in
blood soluble interleukin-2 receptors has a negative
prognostic value even greater than of other quantities -
(histological type, clinical stage, diagnosis of marrow
involvement, lactate dehydrogenase) in predicting the
length of the disease-free interval and overall survival
period (35).
High blood soluble interleukin-2 receptors have also
been found in 70% of Hodgkin's disease patients at
the outset; the values are higher in advanced stages
of the disease (stages III—IV, the presence of bulky
disease) and in the presence of systemic symptoma-
tology, in both adults and children. A good clinical
response to therapy correlates with rapid normaliza-
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Fig. 2: Serum soluble interleukin-2 receptor and urinary neopterin in a longitudinal study of eight patients which achieved
remission.
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tion of the values, while their resurgence generally
indicates a relapse. Abnormally high blood soluble
interleukin-2 receptor concentration is also an impor-
tant index of negative prognosis in Hodgkirfs disease
(22, 34).
The biological mechanisms underlying our clinical
findings are not yet fully understood. In lymphomas
and leukaemias, the concentrations of soluble inter-
leukin-2 receptors in the blood would appear to de-
pend largely on direct neoplastic production, this as-
suming the characteristics of a classical tumour
marker.
In certain cases (as demonstrated by studies on ex-
perimental lymphomas and as appears to occur in
solid tumours), the increase in blood soluble interleu-
kin-2 receptors, unrelated to the expression of inter-
leukin-2 receptors on the membrane of the neoplastic
cells, might .indicate a modified macrophage-related
activation of lymphocytes and/or monocytes which is
of autonomic genesis or induced by the neoplasia (9,
16, 17).
Increases in urine neopterin have been observed to be
correlated strictly with the level of activity of the
disease, be it Hodgkirfs or non-Hodgkin's lymphoma
(correlation being particularly significant in non-
Hodgkin's lymphoma), and are therefore useful in the
clinical monitoring of patients (25, 28, 37). Account
must also be taken of the importance of urinary
neopterin in prognosis: patients with lower urinary
neopterin values survive longer than those with higher
values, regardless of the clinical stage of the disease
(21,24).
In our experience, neopterin concentrations that are
high during the clinical remission phase after induc-
tion therapy (or higher than those at the onset of the
disease) are, compared with other classical quantities,
the most significant in predicting early relapse (25,
28, 29, 30). A recent multivariate survival analysis of
the prognosis of multiple myeloma in fact showed
that the predictive potential of neopterin in serum is
greater than that of interleukin-6, a potent myeloma
cell-growth factor that reflects disease severity in hu-
man plasma cell dyscrasias (38).
The biological mechanisms underlying the variations
in the concentrations of urinary neopterin are as yet
unclear. The increase in the concentrations of neop-
terin excreted in the urine appears first and foremost
to be linked to activation of the immune response (T-
lymphocyte-macrophage system) induced in the host
by specific tumour-cell antigens (19). However, neo-
pterin may also be produced by specific tumour-cell
subclones (14). In any event, activation of cell-medi-
ated immunity often fails to lead to the effective killing
of tumour cells, owing to an excess of antigen or to
altered immune-cell function. • ί
Very recent preliminary studies point to the possible
importance, in cases of neoplasia, of assaying soluble
interleukin-2 receptors and urinary neopterin at the
same time, because high concentrations of soluble
interleukin-2 receptors are reported in the same dis-
eases that feature enhanced excretion of neopterin in
the urine (39, 40).
To conclude, the results of our novel study of blood
soluble interleukin^2 receptors and concomitant uri-
nary neopterin confirms the importance of these two
quantities as putative clinical markers in cases of
lymphoma. The increases in concentrations reflect the
development of the disease during the active stages,
while decreasing concentrations correlate with the de-
gree of response to therapy. The overall increase at
the onset of the disease assumes a specific negative
prognostic significance in the prediction of the interval
of freedom from the disease and ultimate survival.
However, a clearer picture emerges from urinary
neopterin values; they correlate more closely with
general symptomatology, with the clinical stage and
with the routine analyses.
The observed differences between the two markers
may be related to an ongoing immune response with
peculiar activation of macrophages, which are the
main source of neopterin. Macrophages are also able
to modulate the inflammatory response by interaction
with complement, release of hydrolases and proteases,
the formation of peroxides, and the production of
interleukin 1 and tumour necrosis factor which induce
fever by their action on regulatory centres of the
hypothalamus. From a clinical point of view, the
above mentioned relationships appear to be further
confirmed by the direct and significant correlation
between urinary neopterin concentrations, clinical
variables and general symptomatology.
The extent to which the specific activation of the T-
lymphocyte-macrophage system, as revealed by the
markers in question, depresses or enhances the im-
mune response remains to be clarified.
Finally, the reported (41) increase in blood soluble
interleukin-2 receptors and neopterin concentrations
during immunotherapy of cancer with interleukin-2
emphasizes the need for a detailed study of the various
cytokinetic effects on immune-cell modulation. Such
studies are important for the design of targeting ther-
apy appropriate to individual cases, with a view to
boosting the body's anti-tumoral defences.
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